Daiichi Sankyo Launches Billion-Euro German Expansion

Daiichi Sankyo is spending around EUR one billion on the project, which will bring leading international researchers, engineers and sterile- and bio-technology experts to the Bavarian town.

The project will increase Daiichi Sankyo’s production capacities for cardiovascular medications. The innovation center will also encompass new laboratories for antibody drug conjugates (ADCs) to fight cancer.

“We’re on our way to becoming one of the world’s leading oncology companies,” said Daiichi Sankyo Europe Managing Director and Chairman Masahiro Kato in a statement. “At the same time, we’re building on our long-term successful with cardiovascular medications. By expanding our oncological activities, we hope to make an even greater contribution to medical progress in the future…Our location in Pfaffenhofen with its long-standing expertise offers all the right conditions for this.”

“Daiichi Sankyo’s billion-euro investment is very good news for patients as well as for Germany as a pharmaceutical location,” added German Health Minister Prof. Karl Lauterbach. "Our pharma strategy and the digitalization of our health system strengthen Germany as a research and production location. The research and development of new therapies motivates us as the national German government to accelerate our strategy of promoting pharmaceutical research and production.”